Forsyth Barr highlights 'hidden gem' and growth opportunity at Ebos

Forsyth Barr highlights 'hidden gem' and growth opportunity at Ebos
Ebos has room to grow. (Image: Ebos)
Rebecca Howard
Ebos Group’s Australian Biotechnologies is a "hidden gem" while Transmedic offers a solid platform for future growth, Forsyth Barr analysts said.The two businesses represent about 15% of the group’s FY25 earnings before interest, taxes, depreciation and amortisation and “have higher organic growth than the group over the medium term”, Matt Montgomerie and Benjamin Crozier said.Both were initially acquired as part of its A$1.16 billion (NZ$1.25b)  LifeHealthcare acquisition, which was completed in May 2022....

More Markets

NZ sharemarket continues momentum, Skellerup sees green
Markets Market Close

NZ sharemarket continues momentum, Skellerup sees green

 The Red Band gumboot-maker said it earned $54.5m after tax. 

Tom Raynel 21 Aug 2025
Xero board faces 'first strike' over CEO pay
Markets

Xero board faces 'first strike' over CEO pay

Xero investors fire warning shot at directors willing to pay big for talent.

Staff reporters 21 Aug 2025
Auckland airport dynamics returning to normal
Markets

Auckland airport dynamics returning to normal

Yields are improving for airlines operating into Auckland, but earnings look flat ahead. 

Pattrick Smellie 21 Aug 2025